KEQU
Fiscal year ends April Quarters are offset from the calendar — Q1 is May–Jul

Kewaunee Scientific Corporation is a manufacturer of laboratory, healthcare, and technical furniture and infrastructure products. Founded in 1906, the company designs and installs steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. Through its acquisition of Nu Aire, Inc. in November 2024, the company also produces CO2 incubators, ultralow freezers, animal handling equipment, and pharmacy compounding isolators. The company operates through two segments: the Lab Products Group, which includes operations in Statesville, North Carolina, and the Nu Aire subsidiary in Plymouth, Minnesota, and the International segment, which provides facility design, engineering construction, and project management services. Products are sold to pharmaceutical, biotechnology, industrial, chemical, and commercial research laboratories, educational institutions, healthcare institutions, governmental entities, and manufacturing facilities. The company serves markets in the United States, India, Singapore, and Saudi Arabia, with manufacturing facilities in Statesville, North Carolina, and Bangalore, India. Sales are conducted through direct customer orders, dealers, subsidiaries, and a national distributor.

Summarised from the company's own disclosures, fiscal year ended Jun 2026

Industry Building Products & Equipment Homepage kewaunee.com
Sector Industrials IR page kewaunee.com/about/investor-information
Tags
laboratory furniture, fume hoods, biological safety cabinets, co2 incubators, ultralow freezers, epoxy resin work surfaces, modular systems, pharmacy compounding isolators, facility design, engineering construction, Nu Aire Inc., Nu Aire
Press page kewaunee.com/about/news

Metrics

Valuation  
Market cap $ 99.733M
Market cap (USD) $ 99.733M
P/E 12.48
PEG 0.09
P/BV 1.33
P/S 0.36
P/OCF 6.73
P/FCF 9.17
Dividend yield 0.06%
Turnover / mcap —
Returns  
ROE 13.8%
ROI 10.1%
ROIC 13.4%
Profit margin 3.4%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 135.3%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 25.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 9
Quality score 11.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 281.999M 240.472M 203.755M 219.494M 168.872M 147.469M 147.54M 146.55M 158.05M 138.558M 128.626M 118.828M 0 117.121M 102.847M 100.003M 103.978M 89.51M 81.441M 84.071M 73.481M 94.7M — — 77.059M 74.798M
Net profit 9.618M 11.405M 18.753M 738K -6.126M -3.672M -4.687M 1.529M 5.188M 4.515M 3.802M 3.529M 3.895M 3.044M 1.031M 1.85M 4.247M 3.134M 1.54M 193K -147K 1.462M -342K 1.9M 1.277M 3.561M
Free cash flow 14.696M 12.617M 15.191M -7.938M -9.793M -1.485M 1.696M -1.723M -212K 9.051M 5.084M -277K 6.048M 1.422M 5.488M -3.976M 600K 845K 6.981M -2.132M 2.167M — -1.844M 2.394M 688K -1.157M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 34.27 32.44 34.4 15.23 14.5 12.34 7.94 21.06 34.05 23.01 16.65 17.47 16.3 13 8.6 11.6 9.4 18.16 — — — — — — — —
Price performance 12m 0.06 -0.06 1.26 0.05 0.17 0.55 -0.62 -0.38 0.48 0.38 -0.05 0.07 0.25 0.51 -0.26 -0.17 -0.48 — — — — — — — — —

Filed figures

Figure Apr 2017 Apr 2018 Apr 2019 Apr 2020 Apr 2021 Apr 2022 Apr 2023 Apr 2024 Apr 2025 Apr 2026
Balance sheet detail
Trade receivables (USD) 29.9M 32.7M 33.3M 28.1M 34.1M 41.3M 46.1M 45.1M 62.4M 58.7M
↳ YoY growth +7.4% +9.3% +1.8% -15.6% +21.5% +21.0% +11.7% -2.2% +38.4% -5.8%
↳ 5y CAGR +5.2% +4.8% +7.2% -0.7% +4.1% +6.7% +7.1% +6.3% +17.3% +11.5%
Borrowings, current (USD) 918,000 1.17M 1.17M 0.00 6.83M 1.59M 3.59M 3.1M 3.99M 5.07M
Borrowings, non-current (USD) — 1.26M 229,000 — — — — — 34.7M 15.1M
Lease liabilities (USD) — — 149,000 9.19M 9.32M 7.85M 9.34M 7.9M 12.3M 10.4M
Cash and deposits (USD) 12.5M 9.72M 10.6M 4.37M 5.21M 4.43M 8.08M 23.3M 14.9M 9.95M
Intangible assets (USD) — — — — — — — 0.00 17.8M 16.3M
Right-of-use assets (USD) — — — 9.31M 9.28M 7.57M 9.17M 7.45M 13M 10.8M
Net debt (borrowings + leases - cash) (USD) -11.6M -8.55M -9.25M 4.83M 10.9M 5.01M 4.85M -12.3M 36M 20.6M
Cash flow detail
Operating cash flow (USD) 11.7M 3.18M 2.49M 4.16M 912,000 -7.89M -3.79M 19.6M 14.8M 18.6M
Purchases of property, plant and equipment (USD) -2.61M -3.4M -4.21M -2.47M -2.4M -1.91M -4.15M -4.37M -2.17M -3.94M
Change in receivables (cash effect) (USD) -2.09M -3.12M -664,000 4.83M -6.09M -8.46M -4.95M 741,000 -6.74M 3.3M
Change in inventories (cash effect) (USD) 691,000 -2.73M 456,000 1.88M -1.19M -7.28M 1.91M 1.21M 3.35M 2.32M
Change in payables (cash effect) (USD) 686,000 4.56M -55,000 -2.02M 4.57M 11.9M -5.56M 691,000 583,000 -5.15M
Dividends paid (cash effect) (USD) -1.57M -1.79M -2.03M -1.04M 0.00 — — — — —
Share buybacks (cash effect) (USD) — — — — — — 0.00 -2M -1.6M 0.00
Interest paid (cash effect) (USD) -292,000 -295,000 -352,000 -513,000 -65,000 -480,000 -1.86M -1.8M -3.37M -3.33M
Income taxes paid (cash effect) (USD) -2.62M -2.87M -2.46M -188,000 1.8M -1.01M -3.16M -6.24M -3.97M -3.56M
Share-based compensation (USD) 199,000 355,000 197,000 251,000 634,000 729,000 886,000 1.03M 1.44M 2.13M
Operating cash flow before change in receivables (USD) 13.8M 6.3M 3.15M -672,000 7M 579,000 1.16M 18.8M 21.5M 15.3M
Free cash flow (OCF - PPE - intangibles) (USD) 9.05M -212,000 -1.72M 1.7M -1.49M -9.79M -7.94M 15.2M 12.6M 14.7M
Income detail
Research and development expense (USD) 1.16M 1.54M 1.55M 1.82M 1.41M 990,000 1.01M 920,000 919,000 898,000
↳ 5y CAGR +4.3% +12.0% +13.0% +14.2% +3.8% -3.2% -8.0% -9.9% -12.7% -8.6%
Total comprehensive income (USD) 5.93M 5.78M 1.18M -7.82M 2.41M -6.17M 1.66M 19.1M 11.2M 9.65M
Comprehensive income to owners (USD) 5.82M 5.61M 1.02M -7.88M 2.35M -6.29M 1.04M 18.8M 11M 8.81M
Provision for credit losses (USD) 37,000 344,000 65,000 364,000 53,000 92,000 120,000 276,000 68,000 343,000
Credit cost ratio (credit losses / average receivables) (%) 0.1% 1.1% 0.2% 1.2% 0.2% 0.2% 0.3% 0.6% 0.1% 0.6%
Reported Jul 21, 2017 Jul 11, 2019 Jul 27, 2020 Jul 27, 2020 Jul 15, 2021 Jul 1, 2022 Jun 28, 2024 Mar 14, 2025 Jul 2, 2025 Jun 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Exchange: NASDAQ (KEQU) Contact: Donald T. Gardner III

704/871-3274

STATESVILLE, N.C. November 2, 2026 – PRNewswire / Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that it has entered into a definitive agreement to acquire Nycom, Inc. (“Nycom”), the largest lab dealer in the USA. The proposed acquisition represents an important step in Kewaunee’s long-term growth strategy, bringing Nycom’s expertise in laboratory design and project delivery closer together with Kewaunee’s manufacturing capabilities to provide more fully integrated laboratory solutions. The Company intends to leverage Nycom’s scalable world-class operating platform to support organic growth and pursue selective acquisition opportunities across North America.

Kewaunee and Nycom have worked together for decades. During that time, Nycom has earned a strong reputation throughout the industry for exceptional project execution and customer service. Their experienced leadership and established operating organization make Nycom particularly well suited to support Kewaunee’s plans for continued growth.

Exchange: NASDAQ (KEQU) Contact: Donald T. Gardner III

704/871-3274

STATESVILLE, N.C. September 9, 2026 – PRNewswire / Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its first quarter ended July 31, 2026.

Fiscal Year 2027 First Quarter Highlights:

•Backlog increased to $169.0 million on July 31, 2026, up from $165.9 million on April 30, 2026.

•International segment net earnings increased 23.5% and segment EBITDA increased 13.9% despite lower sales as a result of a favorable mix of higher-margin projects.

•Ongoing cost management efforts and improved operating efficiencies helped mitigate the negative impact of lower manufacturing volumes within LPG.

•Higher effective tax rate driven by a greater mix of earnings from international operations relative to domestic operations.

•Long-term debt, excluding the Company's sale-leaseback financing obligation, declined to $13.8 million from $15.1 million on April 30, 2026.

On August 26, 2026, Kewaunee Scientific Corporation (the "Company") held its Annual Meeting of Shareholders (the "Annual Meeting"). At the Annual Meeting, the Company's shareholders voted on the matters set forth below. 1.The nominees named below were re-elected as Class I directors for three-year terms as follows:

Name of Nominee For Withheld Non-Votes Thomas D. Hull III 1,623,693 1,062 892,401 David S. Rhind 1,464,432 160,323 892,401 John D. Russell 1,623,690 1,065 892,401

2.The appointment of the independent registered public accounting firm of Forvis Mazars, LLP as the Company's independent auditors for fiscal year 2027 was ratified as follows:

For Against Abstained 2,516,379 106 671

3.The compensation of the Company's named executive officers in the fiscal year ended April 30, 2026 was approved on an advisory basis as follows:

For Against Abstained Non-Votes 1,586,496 36,616 1,643 892,401

Prompts

Kewaunee Scientific Corporation (ticker KEQU), listed in United States.

ETFs Holding Kewaunee Scientific Corporation

ETF Weight in ETF Shares Market value As of
DFSV 0.01% 51,050 $ 1.835M Nov 12, 2026
DFAT 0.00% 37,769 $ 1.357M Nov 12, 2026
DFAS 0.00% 21,791 $ 783.169K Nov 12, 2026
DXUV 0.00% 2,041 $ 73.354K Nov 12, 2026
DFAC 0.00% 10,054 $ 361.341K Nov 12, 2026
DCOR 0.00% 4,859 $ 174.632K Nov 12, 2026
DFUV 0.00% 1,631 $ 58.618K Nov 12, 2026
DFUS 0.00% 684 $ 24.583K Nov 12, 2026
DFSU 0.00% 39 $ 1,401.66 Nov 12, 2026
AVUS 0.00% 1,303 $ 45.683K Nov 16, 2026
AVUV 0.00% 38,810 $ 1.361M Nov 16, 2026
AVSC 0.00% 3,756 $ 131.685K Nov 16, 2026